A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.

A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future Oncol. 2022 Dec; 18(40):4443-4456.

View in: PubMed

subject areas

Adult
Antineoplastic Combined Chemotherapy Protocols
Bortezomib
Dexamethasone
Hematologic Neoplasms
Humans
Multiple Myeloma

authors with profiles

Andrzej Jakubowiak